Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
28 February 2023 - 08:01AM
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that
it will host a conference call and live webcast on Tuesday,
February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth
quarter and full-year 2022 financial results and recent portfolio
execution.
A live webcast will be accessible through the Investors &
Media section of the company’s website at www.kiniksa.com.
Individuals interested in participating in the call via telephone
may register here. Upon registration, all telephone participants
will receive a confirmation email detailing how to join the
conference call, including the dial-in number along with a unique
passcode and registrant ID that can be used to access the call. A
replay of the event will also be available on Kiniksa’s website
within approximately 48 hours after the event.
About KiniksaKiniksa is a biopharmaceutical
company focused on discovering, acquiring, developing, and
commercializing therapeutic medicines for patients suffering from
debilitating diseases with significant unmet medical need.
Kiniksa’s portfolio of immune-modulating assets, ARCALYST, KPL-404,
and mavrilimumab, are based on strong biologic rationale or
validated mechanisms, target a spectrum of underserved
cardiovascular and autoimmune conditions, and offer the potential
for differentiation. For more information, please
visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron
Pharmaceuticals, Inc.
Every Second
Counts! ®Kiniksa Investor and
Media ContactRachel Frank(339)
970-9437rfrank@kiniksa.com |
|
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Mar 2023 to Mar 2024